[go: up one dir, main page]

MA29265B1 - Derives de 3-aryl-1, 2-benzisoxazole, et leur utilisation comme medicaments contre le cancer - Google Patents

Derives de 3-aryl-1, 2-benzisoxazole, et leur utilisation comme medicaments contre le cancer

Info

Publication number
MA29265B1
MA29265B1 MA30161A MA30161A MA29265B1 MA 29265 B1 MA29265 B1 MA 29265B1 MA 30161 A MA30161 A MA 30161A MA 30161 A MA30161 A MA 30161A MA 29265 B1 MA29265 B1 MA 29265B1
Authority
MA
Morocco
Prior art keywords
aryl
nr5r6
nitro
halogen
cancer drugs
Prior art date
Application number
MA30161A
Other languages
English (en)
Inventor
Luc Bertin
Chantal Carrez
Fabienne Thompson
Patrick Maillet
Jean-Marie Ruxer
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35058405&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA29265(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of MA29265B1 publication Critical patent/MA29265B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

L'INVENTION CONCERNE LES NOUVEAUX PRODUITS DE FORMULE (I): DANS LAQUELLE A1 ET A2 REPRÉSENTENT CH OU N; X REPRÉSENTE CRA OU N; Y REPRÉSENTE CRB OU N; R1, R2, R3 ET R4 IDENTIQUES OU DIFFÉRENTS REPRÉSENTENT NOTAMMENT HYDROGÈNE, HALOGÈNE, CYANO, NITRO, TRIFLUOROMÉTHYLE, OR5, SR5, NR5R6, C(O)R5, C(O)OR5, C(O) NR5R6, S(O)R5, S(O)2R5, S(O)NR5R6, S(O)2NR5R6, NR6C(O)R5, NR6C(O)OR5, ALKYLES, ALKÉNYLES, ALKYNYLES, ARYLES, HÉTÉROARYLES, ARALKYLES OU HÉTÉROARALKYLES, TOUS ÉVENTUELLEMENT SUBSTITUÉS; RA REPRÉSENTE NOTAMMENT HALOGÈNE, HYDROXYLE, ALCOXY, NITRO; RB REPRÉSENTE NOTAMMENT HYDROGÈNE, HALOGÈNE, CYANO, NITRO, TRIFLUOROMÉTHYLE, -W-(CI- C3ALKYLE)M- R5 ; R5 ET R6 REPRÉSENTE NOTAMMENT ALKYLE, ARALKYLE OU HÉTÉROARALKYLES ÉVENTUELLEMENT SUBSTITUÉS; CES PRODUITS ÉTANT SOUS TOUTES LES FORMES ISOMÈRES ET LES SELS, À TITRE DE MÉDICAMENTS.
MA30161A 2005-02-22 2007-08-23 Derives de 3-aryl-1, 2-benzisoxazole, et leur utilisation comme medicaments contre le cancer MA29265B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0501801A FR2882361A1 (fr) 2005-02-22 2005-02-22 Nouveaux derives de 3-aryl-1,2-benzisoxazole, compositions les contenant et leur utilisation

Publications (1)

Publication Number Publication Date
MA29265B1 true MA29265B1 (fr) 2008-02-01

Family

ID=35058405

Family Applications (1)

Application Number Title Priority Date Filing Date
MA30161A MA29265B1 (fr) 2005-02-22 2007-08-23 Derives de 3-aryl-1, 2-benzisoxazole, et leur utilisation comme medicaments contre le cancer

Country Status (19)

Country Link
US (1) US20080070960A1 (fr)
EP (1) EP1861381A1 (fr)
JP (1) JP2008531493A (fr)
KR (1) KR20070110102A (fr)
CN (1) CN101146780A (fr)
AR (1) AR053684A1 (fr)
AU (1) AU2006217799A1 (fr)
BR (1) BRPI0606178A2 (fr)
CA (1) CA2597781A1 (fr)
EA (1) EA200701798A1 (fr)
FR (1) FR2882361A1 (fr)
IL (1) IL185166A0 (fr)
MA (1) MA29265B1 (fr)
MX (1) MX2007010278A (fr)
NO (1) NO20074631L (fr)
TW (1) TW200640884A (fr)
UY (1) UY29390A1 (fr)
WO (1) WO2006090052A1 (fr)
ZA (1) ZA200707080B (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2907453B1 (fr) 2006-10-24 2008-12-26 Sanofi Aventis Sa Nouveaux derives du fluorene,compositions les contenant et utilisation
AR077405A1 (es) 2009-07-10 2011-08-24 Sanofi Aventis Derivados del indol inhibidores de hsp90, composiciones que los contienen y utilizacion de los mismos para el tratamiento del cancer
FR2949467B1 (fr) 2009-09-03 2011-11-25 Sanofi Aventis Nouveaux derives de 5,6,7,8-tetrahydroindolizine inhibiteurs d'hsp90, compositions les contenant et utilisation
SMT201800070T1 (it) * 2012-12-19 2018-03-08 Celgene Quanticel Res Inc Inibiorti di istone demetilasi

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6884814B2 (en) * 2001-12-13 2005-04-26 Wyeth Phenyl benzisoxazoles as estrogenic agents
EA009919B1 (ru) * 2003-02-11 2008-04-28 Вернэлис (Кембридж) Лимитед Соединения изоксазола
US7538224B2 (en) * 2003-06-27 2009-05-26 Kyowa Hakko Kogyo Co., Ltd. Hsp90 family protein inhibitors
WO2005019151A1 (fr) * 2003-08-20 2005-03-03 Eli Lilly And Company Modulateurs du recepteur active de la proliferation des peroxysomes (ppar)

Also Published As

Publication number Publication date
NO20074631L (no) 2007-11-20
IL185166A0 (en) 2007-12-03
MX2007010278A (es) 2007-11-07
CA2597781A1 (fr) 2006-08-31
AR053684A1 (es) 2007-05-16
TW200640884A (en) 2006-12-01
CN101146780A (zh) 2008-03-19
EA200701798A1 (ru) 2008-02-28
UY29390A1 (es) 2006-10-02
EP1861381A1 (fr) 2007-12-05
US20080070960A1 (en) 2008-03-20
BRPI0606178A2 (pt) 2009-06-02
JP2008531493A (ja) 2008-08-14
WO2006090052A1 (fr) 2006-08-31
KR20070110102A (ko) 2007-11-15
FR2882361A1 (fr) 2006-08-25
ZA200707080B (en) 2008-11-26
AU2006217799A1 (en) 2006-08-31

Similar Documents

Publication Publication Date Title
Bhagat et al. Design, synthesis, antimicrobial evaluation, and molecular modeling studies of novel indolinedione–coumarin molecular hybrids
IL278297B2 (en) Substituted heterocyclic inhibitors of ptpn11
Huang et al. Searching for new cures for tuberculosis: design, synthesis, and biological evaluation of 2-methylbenzothiazoles
Pan et al. Thiazolidione derivatives as novel antibiofilm agents: Design, synthesis, biological evaluation, and structure–activity relationships
CY1113846T1 (el) Παραγωγα πυριμιδινης για την θεραπευτικη αντιμετωπιση του ασθματος, copd, αλλεργικης ρινιτιδας, αλλεργικης επιπεφυκιτιδας, ατοπικης δερματιτιδας, καρκινου, ηπατιτιδας β, ηπατιτιδας c, hiv, hpv, βακτηριακων λοιμωξεων και δερματωσης
TW200510442A (en) Condensed beterocyclic derivatives, pharmaceutical compositions comprising the same, and pharmaceutical uses thereof
JP2015143283A5 (fr)
MA31419B1 (fr) Derives de pyridine
MA29649B1 (fr) Nouveaux derives de 2,4- dianilinopyrimidines, leur preparation, a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk
HUP0402352A2 (hu) Foszfodiészteráz (PDE) 7 inhibitorként alkalmazható pirimidinszármazékok és ezeket tartalmazó gyógyszerkészítmények
CY1120081T1 (el) Παραγωγα hydroxybenzamide σαν παραγοντες καταστολης της hsp90
Patel et al. In vitro and in vivo assessment of newer quinoxaline–oxadiazole hybrids as antimicrobial and antiprotozoal agents
CY1111980T1 (el) Παραγωγα του αμιδιου τα οποια φερουν ενα υποκαταστατο του κυκλοπροπυλαμινοκαρβονυλιου και χρησιμευουν ως αναστολεις κυτταροκινης
Cholewiński et al. Synthesis of the inosine 5′-monophosphate dehydrogenase (IMPDH) inhibitors
MA33501B1 (fr) Nouveaux derives de (6-oxo-1,6-dihydro-pyrimidin-2-yl)-amide, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt(pkb)
CY1108632T1 (el) Παραγωγα της 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline για θεραπεια της στειροτητας
MA29265B1 (fr) Derives de 3-aryl-1, 2-benzisoxazole, et leur utilisation comme medicaments contre le cancer
MXPA05014068A (es) Dicetopiperazinas sustituidas y su uso como antagonistas de oxitocina.
Ahmed et al. Synthesis and Anticonvulsant Activity of Some Substituted Azetidinone Derivatives
Kabi et al. Overview on diverse biological activities of benzisoxazole derivatives
UY29739A1 (es) Derivados de amidas o sales farmacéuticamente aceptables de los mismos, procesos de preparaciones farmacéuticas conteniéndolos y aplicaciones
HUP0203161A2 (hu) Benzamidinszármazékok, eljárás az előállításukra, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
EE05300B1 (et) Akrloldistamtsiini derivaati sisaldav farmatseutiline kompositsioon, derivaadi kasutamine tuumorivastase ravimi valmistamiseks ning kombineeritud ravimpreparaat
NO20055997L (no) Diarylmetylidenpiperidinderivater og deres anvendelse som opiodreseptoragonister
MA27091A1 (fr) Nouveaux derives de benzothiazine et benzothiadiazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent